Rowan Chapman

Dr. Chapman is a founder, investor and active independent board member of public and private companies. She works with entrepreneurs to create and scale meaningful new ventures. She is an Executive Leader for startups to Fortune 50 companies and has significant experience in building successful teams, developing and executing business plans, equity investing, licensing, and business development. Dr. Chapman has been an advisor in several initiatives, including solving global challenges to drive sustainable impact in health, and improve health outcomes through clinically and economically beneficial digital health solutions and new approaches to predictive analytics. Dr. Chapman previously held senior roles at J&J, GE, Mohr Davidow Ventures, and several startups. In these roles she partnered with entrepreneurs to launch, invest and build companies such as Evidation Health, Adamas (IPO: ADMS), RainDance (acquired: BioRad), pacific Biosciences (IPO: PACB), ParAllele (acquired: AFFX), Sequenta (acquired: ADPT), and Verinata (acquired: ILMN). She holds BA and Ph.D. degrees from the University of Cambridge, UK.